Title : Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.

Pub. Date : 2010 Mar 10

PMID : 20142590






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PATIENTS AND METHODS: Imatinib therapy was stopped in 20 patients who had concomitantly been pretreated with imatinib and IFN for a median of 2.4 years (range, 0.2 to 4.8 years) and 2.5 years (range, 0.2 to 4.9 years), respectively. Imatinib Mesylate interferon alpha 1 Homo sapiens
2 CONCLUSION: Treatment with IFN enables discontinuation of imatinib in most patients after prior imatinib/IFN combination therapy and may result in improved molecular response. Imatinib Mesylate interferon alpha 1 Homo sapiens
3 CONCLUSION: Treatment with IFN enables discontinuation of imatinib in most patients after prior imatinib/IFN combination therapy and may result in improved molecular response. Imatinib Mesylate interferon alpha 1 Homo sapiens